NCT00092534 2025-08-01
FUTURE II
Merck Sharp & Dohme LLC
Phase 3 Completed
Clinical Trials
8 trialsNCT05149248 2021-12-08
CONDESA
Instituto Nacional de Salud Publica, Mexico
Phase 2/3 Completed
NCT01245764 2018-11-14
GARDASILâ„¢ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00524745 2017-04-14
Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil
PATH
Phase NA Completed
NCT00092482 2017-03-22
Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00517309 2017-03-22
FUTURE
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00551187 2015-06-08
A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00092495 2015-01-13
Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)
Merck Sharp & Dohme LLC
Phase 3 Completed